Yannaki Evangelia, Anagnostopoulos Achilles, Kapetanos Demetrios, Xagorari Angeliki, Iordanidis Fotis, Batsis Ioannis, Kaloyannidis Panayotis, Athanasiou Evangelia, Dourvas Georgios, Kitis Georgios, Fassas Athanasios
Hematology Department-BMT Unit and Gene and Cell Therapy Center, George Papanicolaou Hospital, Thessaloniki, Greece.
Exp Hematol. 2006 Nov;34(11):1583-7. doi: 10.1016/j.exphem.2006.06.012.
For end-stage liver disease, liver transplantation provides the only definite cure; however, many patients die while in the waiting list for donation. Various stem cell populations have been described to contribute to liver regeneration and there is accumulating evidence for the participation of hematopoietic stem cells (HSCs) in this process. We here report two cases treated with boost infusions of autologous mobilized HSCs to regenerate cirrhotic liver. The procedure was safe and well tolerated. Both patients showed a lasting amelioration in the clinical course of the disease during the 30 months of follow-up. These results suggest that the procedure may be considered in a clinical study setting as a bridging therapy until organ transplantation becomes available or to reverse a decompensated cirrhosis to a compensated one. Additional studies in this area will be required to document efficacy and evaluate toxicity.
对于终末期肝病，肝移植是唯一确切的治愈方法；然而，许多患者在等待器官捐献的过程中死亡。多种干细胞群体已被描述为有助于肝脏再生，并且有越来越多的证据表明造血干细胞（HSCs）参与了这一过程。我们在此报告两例接受自体动员造血干细胞强化输注以再生肝硬化肝脏治疗的病例。该 procedure 安全且耐受性良好。两名患者在 30 个月的随访期间疾病临床进程均出现持续改善。这些结果表明，在临床研究环境中，该 procedure 可被视为一种桥接治疗，直至可进行器官移植，或将失代偿性肝硬化转变为代偿性肝硬化。需要在该领域进行更多研究以证明疗效并评估毒性。
